0000000000701711

AUTHOR

Benjamin Brenner

showing 3 related works from this author

Women, thrombosis, and cancer: A gender-specific analysis.

2017

Venous thromboembolism (VTE) is a major common complication in cancer patients. Risk-adapted thromboprophylaxis and antithrombotic therapy for patients diagnosed with VTE can reduce the recurrence of VTE events. Thrombotic risk varies according to cancer type, stage, and comorbidities. The current review analyzes most recent data and provides clinical guidance for the management of women with cancer-associated thrombosis.

medicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentPregnancy Complications CardiovascularLow molecular weight heparin030204 cardiovascular system & hematologyPregnancy Complications Cardiovascular/drug therapy/epidemiology03 medical and health sciences0302 clinical medicinePregnancyRisk FactorsInternal medicineNeoplasmsAntithromboticMedicineHumanscardiovascular diseasesddc:616Venous Thromboembolism/drug therapy/epidemiologybusiness.industryAromatase InhibitorsAnticoagulantCancerAnticoagulantsThrombosisHematologyVenous Thromboembolismmedicine.diseaseequipment and suppliesThrombosisNeoplasms/complications/epidemiologySurgeryPostmenopauseVenous thrombosisAnticoagulants/therapeutic use030220 oncology & carcinogenesisFemaleHormone therapybusinessComplicationPregnancy Complications NeoplasticPregnancy Complications Neoplastic/epidemiologyThrombosis/drug therapy/epidemiologyAromatase Inhibitors/therapeutic useThrombosis research
researchProduct

Dabigatran after Short Heparin Anticoagulation for Acute Intermediate-Risk Pulmonary Embolism: Rationale and Design of the Single-Arm PEITHO-2 Study

2017

AbstractPatients with intermediate-risk pulmonary embolism (PE) may, depending on the method and cut-off values used for definition, account for up to 60% of all patients with PE and have an 8% or higher risk of short-term adverse outcome. Although four non-vitamin K-dependent direct oral anticoagulants (NOACs) have been approved for the treatment of venous thromboembolism, their safety and efficacy as well as the optimal anticoagulation regimen using these drugs have not been systematically investigated in intermediate-risk PE. Moreover, it remains unknown how many patients with intermediate-high-risk and intermediate-low-risk PE were included in most of the phase III NOAC trials. The ongo…

MaleRiskmedicine.medical_specialtypulmonary embolismDrug-Related Side Effects and Adverse Reactionsmedicine.medical_treatmentHemorrhageintermediate risk030204 cardiovascular system & hematologyDabigatran03 medical and health sciencesYoung Adult0302 clinical medicineRecurrenceInternal medicineGermanymedicineHumansdabigatran030212 general & internal medicineProspective StudiesProspective cohort studySurvival analysisvenous thromboembolism recurrencebusiness.industryHeparinAnticoagulantsHematologyThrombolysisHeparinReference Standardsmedicine.diseaseThrombosisSurvival Analysis3. Good healthPulmonary embolismright ventricular functionRegimenTreatment OutcomeResearch Designmajor bleedingAcute Diseasedabigatran; intermediate risk; major bleeding; pulmonary embolism; right ventricular function; venous thromboembolism recurrenceFemalebusinessmedicine.drugFollow-Up Studies
researchProduct

Inverse PAR1 Activity of Hematopoietic Stem Cells and BM Stromal Cells Mediates G-CSF-Induced Mobilization By Regulation of Nitric Oxide Generation

2016

Abstract Hematopoietic stem and progenitor cell (HSPC) egress from the bone marrow (BM) to the circulation is tightly regulated and is accelerated during stress conditions, a process utilized for BM harvest. Recently, we demonstrated that mouse long term repopulating hematopoietic stem cell (LT-HSC) BM retention and their rapid release to the blood circulation are governed by a switch in nitric oxide (NO) generation via distinct coagulation-related protease activated receptor 1 (PAR1) cascades (Gur-Cohen S. et al., NM, 2016). Herein we report that surface PAR1 expression can be exploited and serve as a positive predictive marker for the efficiency of human CD34+ HSPC mobilization among heal…

0301 basic medicineStromal cellbiologyChemistryImmunologyMesenchymal stem cellHematopoietic stem cellCell BiologyHematologyBiochemistryCell biology03 medical and health sciencesHaematopoiesis030104 developmental biologymedicine.anatomical_structuremedicinebiology.proteinStromal cell-derived factor 1Progenitor cellStem cellHematopoietic Stem Cell MobilizationBlood
researchProduct